Herbs (Global Traditional) · Southeast Asian
Meniran (Phyllanthus niruri) (Phyllanthus niruri)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Phyllanthus niruri is a tropical herb containing lignans like phyllanthin and hypophyllanthin that support liver function through hepatoprotective mechanisms. The plant's bioactive compounds demonstrate antiviral, hypoglycemic, and nephroprotective effects in preclinical studies.
Phyllanthus niruri, commonly known as meniran, is a small herbaceous plant native to tropical regions of South America and Asia, belonging to the Phyllanthaceae family. The herb is traditionally extracted as decoctions from aerial parts (leaves and stems) or as standardized extracts containing lignans (phyllanthin and hypophyllanthin), flavonoids, tannins, and other polyphenolic compounds.
Human clinical evidence remains limited and predominantly preliminary, with references to a 2011 Journal of Ethnopharmacology study and 2008 Virology Journal study, though specific PMIDs and methodological details are not provided. Most evidence derives from in vitro and animal models, with one small open-label trial showing modest improvements in liver markers and lipid profiles after 8 weeks of supplementation.
Traditional decoction: 4-8g dried herb powder in 300ml water, simmered 10-15 minutes, two cups daily. Standardized extracts: 150-300mg twice daily, standardized to 0.5-1% phyllanthin content. Extract ratios of 2:1 or 4:1 are common. Consult a healthcare provider before starting any new supplement.
Meniran (Phyllanthus niruri) is primarily valued as a medicinal herb rather than a macronutrient source, so nutritional profiling focuses heavily on bioactive compounds rather than caloric content. **Macronutrients (per 100 g dried herb, approximate):** Protein: 8–12 g; Crude fiber: 15–22 g; Fat: 2–4 g; Carbohydrates: 45–55 g; Ash/mineral content: 8–12 g. **Key Bioactive Compounds:** • **Lignans:** Phyllanthin (0.5–1.5% w/w of dried leaf) and hypophyllanthin (0.3–0.8% w/w) — primary hepatoprotective agents; lipophilic, with moderate oral bioavailability enhanced by co-occurring tannins. • **Tannins:** Ellagitannins including corilagin (up to 0.4% w/w), geraniin (0.2–0.7% w/w), and phyllanthusiin D — responsible for antiviral and antioxidant activity; bioavailability is limited due to high molecular weight but gut microbial metabolism yields bioactive urolithins. • **Flavonoids:** Quercetin (0.1–0.3% w/w), rutin (0.05–0.2% w/w), astragalin, and kaempferol glycosides — contribute to antioxidant and anti-inflammatory effects; glycosylated forms have improved water solubility but require intestinal hydrolysis for absorption. • **Alkaloids:** Securinine and norsecurinine (trace amounts, <0.05% w/w); 4-methoxy-securinine reported in some accessions. • **Terpenoids:** Lupeol (~0.1% w/w) and phyllanthenol — anti-inflammatory and mild analgesic properties. • **Organic acids:** Gallic acid (0.2–0.5% w/w), ellagic acid (0.1–0.3% w/w), and amariinic acid — good oral bioavailability for gallic acid (~30–40%); ellagic acid is poorly absorbed but microbially converted. **Minerals (per 100 g dried herb, approximate):** Calcium: 800–1,500 mg; Potassium: 1,200–2,000 mg; Iron: 15–30 mg; Magnesium: 200–400 mg; Phosphorus: 150–300 mg; Zinc: 3–6 mg. **Vitamins:** Vitamin C: 10–25 mg/100 g fresh herb; modest amounts of B-complex vitamins (thiamine, riboflavin). **Bioavailability Notes:** Phyllanthin and hypophyllanthin are lipophilic lignans with enhanced absorption when consumed with dietary fats or formulated with lipid-based carriers. Geraniin and corilagin undergo extensive first-pass metabolism; traditional aqueous decoction extraction yields moderate tannin recovery (~40–60%). Overall phenolic bioavailability is improved by traditional boiling preparation, which increases extraction efficiency of polar compounds by 30–50% compared to cold infusion. Standardized extracts are typically normalized to phyllanthin content (≥2%) for therapeutic consistency.
Lignans including phyllanthin and hypophyllanthin provide hepatoprotection by reducing oxidative stress and inhibiting cytochrome P450-mediated toxicity. The compounds modulate glucose metabolism through enhanced insulin sensitivity and GLUT4 transporter activity. Antiviral effects occur through inhibition of viral DNA polymerase and reverse transcriptase enzymes.
Animal studies demonstrate liver protection with significant reductions in ALT and AST enzymes following CCl₄-induced injury. Rodent diabetes models show improved glucose tolerance and insulin sensitivity at 200 mg/kg doses over 4-8 week periods. Limited human trials suggest potential hepatitis B antigen reduction, though larger controlled studies are needed. Most evidence remains at the preclinical stage with promising but preliminary human data.
Generally well-tolerated in traditional use with mild gastrointestinal effects reported occasionally. May enhance hypoglycemic effects of diabetes medications requiring blood sugar monitoring. Potential interactions with hepatic drug metabolism through cytochrome P450 modulation. Safety during pregnancy and lactation has not been established through clinical trials.
